ライフサイエンスコーパス: lipopeptide

1 bserved antibacterial activity of this novel lipopeptide.

2 by Myrcludex B, a synthetic N-acylated preS1 lipopeptide.

3 tely 20 times less fluorescent than the free lipopeptide.

4 MBP with the negatively charged, dye-labeled lipopeptide.

5 NRPS cluster that generates a seven-residue lipopeptide.

6 wn for the Pam(3)CysSerLys(4) (Pam(3)CSK(4)) lipopeptide.

7 ramagnetic lipid and a fluorescently labeled lipopeptide.

8 to Francisella lipoproteins and triacylated lipopeptide.

9 to recognize TUL4, FTT1103, and triacylated lipopeptide.

10 ase K digestion, suggesting involvement of a lipopeptide.

11 antibacterial activity of the nisin-derived lipopeptides.

12 the binding and insertion process for these lipopeptides.

13 is induced in response to microbial acylated lipopeptides.

14 with a mixture of the three CD4-CD8 HSV-1 gD lipopeptides.

15 peptide are involved in CD1c presentation of lipopeptides.

16 base lysine amino group to construct CD4-CD8 lipopeptides.

17 TLR2-TLR1 heterodimers recognize triacylated lipopeptides.

18 e second member of the CD1 family to present lipopeptides.

19 ymatic cleavage of the liposome-incorporated lipopeptides.

20 ith fatty acids to prepare the corresponding lipopeptides.

21 12, is required for the sensing of bacterial lipopeptides.

22 roduction of six structurally related linear lipopeptides.

23 ll-like receptor (TLR) ligands except diacyl lipopeptides.

24 e peptide component of didehydroxymycobactin lipopeptides.

25 to discriminate between structurally similar lipopeptides.

26 ues of lycosin-I, generating eight different lipopeptides.

27 ular patterns, including di- and triacylated lipopeptides.

28 compared with SVLPs lacking immunomodulatory lipopeptides.

29 eceptor 1/2 (TLR1/2) activation by bacterial lipopeptides.

30 uantity of stereoisomers of bacteria-derived lipopeptides.

31 volutionary branch of the Pseudomonas cyclic lipopeptides.

32 tivity and selectivity of B. subtilis QST713 lipopeptides.

33 receptor stimulation by pathogen-associated lipopeptides.

34 tration of palmitate, fibroblast-stimulating lipopeptide-1, a known TLR2 ligand, was a slightly more

35 eoisomer of diacylated macrophage-activating lipopeptide 2 (MALP-2) exclusively activates epithelial

36 re effective than gelatin film enriched with lipopeptides (2.5%, w/w of gelatin) as a coating, in inh

37 TLR2 agonists such as macrophage-activating lipopeptide-2, activity of the M. arthritidis-derived 28

38 with a TLR2/6 ligand, macrophage-activating lipopeptide-2, or a TLR3 ligand, polyinosinic-polycytidy

39 s when stimulated with macrophage-activating lipopeptide-2, polyinosinic-polycytidylic acid, or UVB (

40 2)-dependent manner by macrophage-activating lipopeptide-2.

41 the fact that the effect of cell-penetrating lipopeptide (a pepducin), suggested to act primarily thr

42 Secretion of IL-1beta in response to lipopeptide, a TLR2 agonist, was greatly reduced in ASC-

43 To investigate the newly emerging roles of lipopeptides, accurate measurements of stereoisomers wit

44 The antifungal echinocandin lipopeptide, acrophiarin, was circumscribed in a patent

45 Cyclic lipopeptides act against a variety of plant pathogens an

46 idual lipid components in model membranes on lipopeptide activity.

47 imed to investigate the potential of a novel lipopeptide/adenovirus type 5 (Lipo/rAdv5) prime/boost m

48 After incubating CD1a with a mycobacterial lipopeptide Ag, dideoxymycobactin (DDM), we identified a

49 The lipopeptides aggregate in the lipopolysaccharide headgro

50 of TLR1 and TLR2 and a synthetic triacylated lipopeptide agonist.

51 we describe the discovery of a new group of lipopeptide aldehydes, the flavopeptins, and the corresp

52 isolation of the highly N-methylated linear lipopeptides, almiramides A-C (1-3).

53 Pam(3)Cys, a synthetic lipopeptide, also induced SOCS1/SOCS3 expression under t

54 Antimicrobial lipopeptides (AMLPs) are antimicrobial drug candidates t

55 usters responsible for the production of the lipopeptide anabaenolysin.

56 nd to a synthetic tripalmitoylated bacterial lipopeptide analogue (Pam(3)CSK(4)).

57 ibitors, and new lincosamide, oxazolidinone, lipopeptide and cephalosporin derivatives.

58 ssion in response to a synthetic triacylated lipopeptide and lipopolysaccharide, respectively, as wel

59 h between the acyl chains of the synthesized lipopeptide and phospholipid components of the liposomes

60 expected mechanism of action for this unique lipopeptide and suggest future development of this and s

61 s greatly impaired in mediating responses to lipopeptides and a variety of other bacterial agonists f

62 TLR1, revealed that TLR10 senses triacylated lipopeptides and a wide variety of other microbial-deriv

63 th TLR1 and TLR6, is essential for detecting lipopeptides and bacterial cell wall components such as

64 cluding biosurfactants such as antimicrobial lipopeptides and saponins, often show a superior perform

65 T cells induced by these molecularly defined lipopeptides and their protective efficacy were assessed

66 enantiomer of MALP-2 (a diacylated bacterial lipopeptide) and to lipoteichoic acid.

67 covalently linked to a palmitic acid moiety (lipopeptides) and delivered subcutaneously in adjuvant-f

68 mouse models of inflammation: LPS, bacterial lipopeptide, and polymicrobial intra-abdominal sepsis.

69 lipid A or lipopolysaccharide, rhamnolipids, lipopeptides, and acyl-homoserine-lactones-do not trigge

70 TLR2 recognizes bacterial lipoproteins/lipopeptides, and lipopolysaccharide activates TLR4.

71 naturally occurring lipoproteins, synthetic lipopeptides, and small heterocyclic molecules.

72 A-F, three structurally diverse alkynylated lipopeptides, and their brominated analogues, from the c

73 dy, we developed pepducins, cell-penetrating lipopeptide antagonists of CXCR4, to interdict CXCL12-CX

74 f the labeled Trp into the calcium-dependent lipopeptide antibiotic (CDA4a).

75 The lipopeptide antibiotic daptomycin (DAP) is a key drug ag

76 A54145 is a lipopeptide antibiotic related to daptomycin that permea

77 a sp. CNQ-490 and produced the dichlorinated lipopeptide antibiotic taromycin A in the model expressi

78 acid was naturally found as a residue in the lipopeptide antibiotic taromycin.

79 Daptomycin is a new lipopeptide antibiotic that is rapidly bactericidal agai

80 Daptomycin is a lipopeptide antibiotic that is used clinically against m

81 Daptomycin is an acidic lipopeptide antibiotic that, in the presence of calcium,

82 Daptomycin is a lipopeptide antibiotic used clinically for the treatment

83 Laspartomycin C is a lipopeptide antibiotic with activity against a range of

84 Daptomycin is a lipopeptide antibiotic with activity against several imp

85 Daptomycin, a lipopeptide antibiotic with activity against virtually a

86 ss spectrometry revealed surfactin, a cyclic lipopeptide antibiotic, as the inhibitory compound.

87 Daptomycin, a novel cyclic lipopeptide antibiotic, exhibits rapid bactericidal acti

88 lated from soil and found to produce a novel lipopeptide antibiotic.

89 activity-toxicity of this important class of lipopeptide antibiotics.

90 (3mGlu) has been found only in three cyclic lipopeptide antibiotics: daptomycin and the A21978C fami

91 and for CD1a demonstrates how a nonribosomal lipopeptide antigen is presented to T cells.

92 ce quenching during loading of a dodecameric lipopeptide antigen, provides a compelling model by whic

93 ediates T cell recognition of glycolipid and lipopeptide antigens that contain either one or two alky

94 The lipopeptide antimicrobial daptomycin has in vitro bacter

95 Daptomycin is a lipopeptide antimicrobial that is rapidly bactericidal a

96 h both the lipid and peptide moieties of the lipopeptide are involved in CD1c presentation of lipopep

97 Antimicrobial peptides and lipopeptides are a promising category of candidates, but

98 Isolated or synthetic lipopeptides are potent vaccine adjuvants, interacting w

99 2 with its lipid A moiety, whereas bacterial lipopeptides are recognized by TLR2.

100 acterial species revealed that the antigenic lipopeptides are specific for strains of the M. tubercul

101 Collagen-mimetic peptides and lipopeptides are widely used as substrates for matrix de

102 ion as criterion when optimizing peptides or lipopeptides as antibiotic leads.

103 2]e(-) reductions to release thioester-bound lipopeptides as corresponding alcohols, using a nonproce

104 egies of introducing ionizable groups on the lipopeptide, as well as the systematic evaluation of che

105 lcium-dependent antibiotics (CDA) are cyclic lipopeptides assembled by nonribosomal peptide synthetas

106 small family of structurally diverse acidic lipopeptides assembled by nonribosomal peptide synthetas

107 a cocrystallized with a synthetic mycobactin lipopeptide at 2.8 A resolution further reveals that the

108 analogue and a molecular subfamily of cyclic lipopeptides, bananamides 1, 2 and 3.

109 nd structure-activity analyses of the cyclic lipopeptide battacin which revealed that conjugation of

110 esis that immunization with self-adjuvanting lipopeptide bearing HSV-1 glycoprotein D (gD) T-cell epi

111 x, SSL3 partially covers the entrance to the lipopeptide binding pocket in TLR2, reducing its size by

112 on of the essential TLR2 dimer interface and lipopeptide-binding channel found in TLR1.

113 these metabolites identified a new class of lipopeptide biosurfactants/biofilm modulators (the malle

114 cluding antibiotics, siderophores and cyclic lipopeptides biosynthesis, some of which were previously

115 (TLR 2/1) and diacylated (TLR 2/6) bacterial lipopeptides (BLPs).

116 (4), and Pam(3)C-Lip, a GC-derived synthetic lipopeptide, but not TLR4 agonists including LPS or GC l

117 nding mechanism of a synthetic antimicrobial lipopeptide, C16-KGGK.

118 other class of peptides, cyclic glycosylated lipopeptides called hassallidins, show antifungal activi

119 as seen in the group that was immunized with lipopeptide can be attributed to an influence on the ada

120 ncerted action of magainin 2, the fungicidal lipopeptide class of surfactins from Bacillus subtilis Q

121 Our earlier work on the monoacyl lipopeptide class of TLR2 agonists led to the design of

122 The MBP-lipopeptide complex serves as a protein substrate for se

123 , by interacting with an already formed TLR2-lipopeptide complex, it prevents TLR heterodimerization

124 f-assembled nanostructures of various hybrid lipopeptides composed of 1:1 alternating alpha- and E-vi

125 ke receptor 2 targeting lipid moiety to form lipopeptide constructs.

126 Vaccination with a mixture self-adjuvanting lipopeptides containing novel HSV-1 immunodominant gD T-

127 was required, as beads coated only with the lipopeptide core failed to delay phagosome-lysosome fusi

128 om Mycobacterium smegmatis are composed of a lipopeptide core unit consisting of a modified C(26)-C(3

129 phobic TLR2 PAMPs within di- and triacylated lipopeptide cores (P2Cys-SVLPs and P3Cys-SVLPs) compared

130 Only SVLPs carrying di- and triacylated lipopeptide cores induced DC activation and maturation i

131 e of the appropriate rIFN-beta, to synthetic lipopeptides corresponding to the triacylated N-terminal

132 These preclinical experiments show that this lipopeptide could form the basis of an optimal needle-fr

133 ompounds other than non-ribosomal antibiotic lipopeptides could be responsible for the antagonistic e

134 The cyclic antimicrobial lipopeptide daptomycin (DAP) triggers the LiaFSR membran

135 ic human pathogen, evolves resistance to the lipopeptide daptomycin and AMPs by diverting the antibio

136 The lipopeptide daptomycin has been approved for use in skin

137 variety of antibiotics including the cyclic lipopeptide daptomycin.

138 Lipopeptides DCS1 are able to preserve the nutritional p

139 The results indicate that lipopeptides DCS1 are effective for the preservation of

140 Furthermore, lipopeptides DCS1 are not toxic to human kidney cells HE

141 sent study aims to investigate the effect of lipopeptides DCS1 on the conservation of food models aga

142 However, examination of a wide variety of lipopeptide derivatives indicates that recognition by hu

143 myristoylated preS-peptide (Myrcludex-B), a lipopeptide derived from the pre-S1 domain of the HBV en

144 Lipopeptides derived from lipoproteins activate innate i

145 nded in a TLR2-dependent manner to bacterial lipopeptides derived from Pseudomonas lipoproteins induc

146 Here we describe lipopeptides derived from the C-terminal heptad repeat (

147 ift in the OM topology of sequence-identical lipopeptides due to a single-variable change in environm

148 52 was attributed to thanamycin, a predicted lipopeptide encoded by a nonribosomal peptide synthetase

149 T cell responses to mycobacterial lipid and lipopeptide-enriched Ag preparations were analyzed in im

150 Amphomycin and MX-2401 are cyclic lipopeptides exhibiting bactericidal activities against

151 ntain Bacillus subtilis strains that produce lipopeptide families, such as surfactins (SF), iturins (

152 chemical and genetic analyses identified the lipopeptide fengycin as the major inhibitory molecule pr

153 ramides A and B are immunosuppressant cyclic lipopeptides first reported from the marine alpha-proteo

154 Besides the specificity of this lipopeptide for MAP, the presence of an N-Me-L-valine re

155 flammatory potency of pnLTA, we generated a (lipopeptide-free) Deltalgt mutant of strain D39Deltacps,

156 Bacaucin, a novel cyclic lipopeptide from Bacillus subtilis CAU21, is reported.

157 crobial products, including lipoproteins and lipopeptides, from a number of pathogens.

158 nthetic TLR2/6 ligand Fibroblast-stimulating lipopeptide (FSL-1) substantially prolongs survival in b

159 lop unique CXCR4-targeted therapeutics using lipopeptide GPCR modulators called pepducins.

160 ed infection in vivo Finally, similar cyclic lipopeptides had no effect on CoV infectivity, and the i

161 Although all the lipopeptides had significantly improved cytotoxicity com

162 To date, pepducins and related lipopeptides have been shown to specifically modulate th

163 ous structure-activity relationships in such lipopeptides have largely been obtained using murine cel

164 inone in clinical use, daptomycin, the first lipopeptide in clinical use, and telithromycin, a ketoli

165 a lipophilic drug in aqueous solution and a lipopeptide in serum.

166 B. subtilis QST713 produces the lipopeptides in a ratio of 6 mol SF: 37 mol FE: 57 mol I

167 The direct incorporation of lipopeptides in ground beef patties at a concentration o

168 heterodimers recognize triacylated bacterial lipopeptides, including the synthetic TLR1/2 lipopeptide

169 tail of these three highly immunogenic Th(1) lipopeptides increased survival, lowered the peak of ocu

170 ra from uninfected cattle, reacted with this lipopeptide, indicating potential biological importance.

171 The current studies revealed that lipopeptide-induced TLR2 signaling inhibited induction o

172 > 32-fold decreased susceptibility) to these lipopeptide inhibitors of cell wall synthesis is rare an

173 ment within bacteria cell walls would impair lipopeptide interaction with cell surface TLR2, requirin

174 ed by CD1 and that the peptide moiety of the lipopeptide is recognized by the TCR.

175 Daptomycin, a cyclic lipopeptide, is the only membrane-active antibiotic appr

176 itrile, a precursor to isonitrile-containing lipopeptides, is biosynthesized by decarboxylation-assis

177 Of the eight lipopeptides, L-C(12) demonstrated highest cytotoxicity

178 Thus, BPPcysMPEG, a novel diacylated lipopeptide ligand for TLR2-TLR6 heterodimer, induces IL

179 cture of a complex between TLR1, TLR2, and a lipopeptide ligand.

180 rs no structural similarity to the canonical lipopeptide ligands of TLR2/TLR1, we investigated how Di

181 peptide epitopes or with Toll-like receptor2 lipopeptide ligands or in three-component vaccines with

182 ide, or mannosyl-phosophomycoketide, but not lipopeptide ligands.

183 previously uncharacterized glycopeptide- and lipopeptide-like antibiotics; thiocoraline-, azinomycin-

184 We report a lipopeptide-like sequence (C10OOc12O) that inflicted out

185 ared with mice immunized with the homologous lipopeptide/lipopeptide (Lipo/Lipo) vaccine, the Lipo/rA

186 Lipopeptide (LP) biosynthesis was induced in Pseudomonas

187 inflammatory responses induced by bacterial lipopeptide, LPS, and TNFalpha.

188 The lipopeptides may therefore be useful as potential immuno

189 Such lipopeptides may therefore be useful in fighting gram-ne

190 The echinocandins are large lipopeptide molecules that, since their discovery approx

191 d microbial agents, including bacterial LPS, lipopeptide, Mycobacterium tuberculosis, cord factor, an

192 llin, cefazolin, or ceftaroline, or a glyco-/lipopeptide (n = 35), that is, vancomycin or daptomycin.

193 llin, cefazolin, or ceftaroline, or a glyco-/lipopeptide (n=35), i.e. vancomycin or daptomycin (VAN/D

194 mplex with a negatively charged, dye-labeled lipopeptide, (N-heptadecanoyl)-K(dye2)-linker-EEIYGEF-am

195 Motivated by lipoproteins, we report lipopeptide nanoparticles as potent and selective siRNA

196 poration of the peptide into self-assembling lipopeptide nanoparticles that mimic native human high d

197 halassospiramides comprise a large family of lipopeptide natural products produced by Thalassospira a

198 e that the mechanism of T cell activation by lipopeptides occurs via ternary interactions of CD1a/Ag/

199 ructural identification of a major cell wall lipopeptide of MAP, termed Para-LP-01, defined as C20 fa

200 -methylated amino acid within an immunogenic lipopeptide of mycobacteria.

201 Fusions of mRFP1 to short N-terminal lipopeptides of OspA, and surprisingly OppAIV, were targ

202 consisting of multiple ultrashort histidine lipopeptides on a triazacyclophane scaffold, which showe

203 ster functionalities in Pam(2)Cys-conjugated lipopeptides on TLR2 activity.

204 present HIV-derived peptides conjugated to a lipopeptide or HIV-infected cells undergoing apoptosis.

205 wn to inhibit signaling induced by bacterial lipopeptide or lipopolysaccharide (LPS), yet the mechani

206 s to nanogram levels of either the synthetic lipopeptide or OspA lipoprotein agonist.

207 ficient" conditions the TLR2/1 ligand 19 kDa lipopeptide or the TLR4 ligand LPS, monocytes showed inc

208 by acting as mobile carriers of triacylated lipopeptides or lipoproteins.

209 andles for the preparation of glycopeptides, lipopeptides or other peptide conjugates; one such trans

210 Injections of tecemotide (806 mug lipopeptide) or placebo were given every week for 8 week

211 We have designed a lipopeptide oral delivery system using a B-cell epitope

212 -activity relationship analyses of 17 linear lipopeptide paenipeptin analogues.

213 lipopeptides, including the synthetic TLR1/2 lipopeptide Pam3CSK4.

214 ysaccharide (LPS) and the synthetic acylated lipopeptide Pam3CSK4.

215 olysaccharide (LPS) or synthetic triacylated lipopeptide (Pam3CSK4) as well as multi-cell computation

216 e to lipoteichoic acid (LTA) and a synthetic lipopeptide (Pam3CSK4) was investigated.

217 controls, and stimulation with the synthetic lipopeptide Pam3Cys, an agonist of TLR1/2, reduced Treg

218 ted outer surface protein A, and triacylated lipopeptide Pam3CysSerLys4 results in the up-regulation

219 New analogues (UPam) of triacylated lipopeptide Pam3CysSK4, a popular agonist of Toll-like r

220 velopment of first-in-class cell-penetrating lipopeptide "pepducin" antagonists of PAR2.

221 his process is blocked by a cell-penetrating lipopeptide "pepducin," P1pal-7, which is a potent inhib

222 tin but not to beta-sheet defensin HNP-1 and lipopeptide polymyxin B.

223 ly, human TLR2 and -6 exclusively respond to lipopeptides possessing a diacylglycerol group.

224 Toll-like receptor 2 (TLR2) agonists are lipopeptides possessing the S-[2,3-bis(palmitoyloxy)prop

225 Our simulations suggest that these lipopeptides prefer to aggregate in solution and alter t

226 Toll-like receptor 1 (TLR2/1) by triacylated lipopeptide, preferentially induced differentiation into

227 panded T cells specifically responded to the lipopeptide preparation.

228 Lipid and lipopeptide preparations as well as complex Ag mixtures,

229 Finally, we showed that bioactive lipopeptides prepared from M. arthritidis grown in serum

230 Surfactin is a cyclic lipopeptide produced by B. subtilis that inhibits the fo

231 Daptomycin, a cyclic lipopeptide produced by Streptomyces roseosporus, is the

232 Anabaenolysins are lipopeptides produced by cyanobacteria with potent lytic

233 rong ermEp* promoter substantially increased lipopeptide production.

234 Lipopeptides promote innate immune response and are rela

235 In contrast, the lipopeptides readily insert into the inner membrane core

236 Injection of radioactively labeled HBVpreS-lipopeptides resulted in rapid accumulation in livers of

237 beta mRNA expression induced by LPS, and the lipopeptides S-[2,3-bis(palmitoyloxy)-(2-RS)-propyl]-N-p

238 ity is extraordinarily challenging given the lipopeptide's extreme hydrophobicity and propensity to m

239 TLR2 binding modes reminiscent of bacterial lipopeptide sensing.

240 he lipid tail to generate a library of novel lipopeptides, some of which were as active as daptomycin

241 ted from marine organisms, we identified the lipopeptide somocystinamide A (ScA) as a pluripotent inh

242 tion that is reversed by the presence of the lipopeptide SP-C.

243 The hypothesis that lipopeptide-specific T cells dominate the early BCG-indu

244 , these studies demonstrate the existence of lipopeptide-specific T cells in humans ex vivo.

245 Nonribosomal lipopeptides such as the plant immunity elicitor surfact

246 y S. coelicolor is inhibited by surfactin, a lipopeptide surfactant produced by B. subtilis.

247 In contrast, the fungicidal lipopeptides surfactin, fengycin, and iturin from Bacill

248 Lipopeptide survived the gastrointestinal conditions, in

249 P. polymyxa mutant deficient in nonribosomal lipopeptide synthesis.

250 eptidase that disrupts interactions with the lipopeptide tail of the antibiotic.

251 -methylated peptide macrocycle attached to a lipopeptide tail, and in the case of the lipoglycopeptid

252 ation, we synthesized analogues with altered lipopeptide tails and identified several with an increas

253 HBVpreS-lipopeptides target to the liver.

254 Surprisingly, natural lipopeptide telomycin precursors were identified when ch

255 The TEM precursor and several semisynthetic lipopeptide TEM derivatives showed rapid bactericidal ki

256 ment of lethal sepsis using cell-penetrating lipopeptides-termed pepducins-that target either individ

257 nificantly enhanced formation of a TLR1.TLR2 lipopeptide ternary complex as measured by size exclusio

258 nt synthesis of the FDA-approved therapeutic lipopeptide tesamorelin and palmitylated variants of the

259 ced MICs; therefore, 50 mug/ml (standard for lipopeptide testing) is recommended.

260 rprising finding of higher potency in linear lipopeptides than their cyclic counterparts is economica

261 ycin and showed that it is a monochlorinated lipopeptide that belongs to the syringomycin family of a

262 nt with the loss of the ability to produce a lipopeptide that functions as a biosurfactant.

263 Daptomycin is a novel cyclic lipopeptide that is approved by the U.S. Food and Drug A

264 Surfactant protein C (SP-C) is a hydrophobic lipopeptide that is critical for lung function, in part

265 tection of Pam3CSK4, a synthetic triacylated lipopeptide that mimics the structural moieties of its n

266 y antigenic, MHC-II-restricted mycobacterial lipopeptides that are recognized by CD4-positive T lymph

267 Pepducins are cell-penetrating lipopeptides that have enabled chemical and physical acc

268 sides A (1) and B (2), a subfamily of acidic lipopeptides that is distinct from previously characteri

269 Three gD lipopeptides, that drive dendritic cell maturation in vi

270 eficient DCs failed to present mycobacterial lipopeptide to T cells but had no defects in endocytosis

271 ymphocyte chimeric epitopes (Th-CTL chimeric lipopeptides) to induce herpes simplex virus type 1 (HSV

272 ge of previously unknown telomycin precursor-lipopeptides, to yield 6-methylheptanoic acid and telomy

273 ngth of protective immunity induced by these lipopeptides together with their safety provide a molecu

274 Intranasal costimulation with the lipopeptide Toll-like receptor (TLR)2/6 agonist, Pam2Cys

275 ance NMR measurements determined that cyclic lipopeptide-treated S. aureus exhibited thinning of the

276 TLR2-specific ligands peptidoglycan and the lipopeptide tri-palmitoyl-S-glyceryl-Cys-Ser-(Lys)(4) th

277 to increase the potency of the antimicrobial lipopeptide tridecaptin A1.

278 Toll-like receptor 2-agonistic lipopeptides typified by S-[2,3-bis(palmitoyloxy)-(2RS)-

279 a series of recently developed antimicrobial lipopeptides, using coarse-grained molecular-dynamics si

280 responses induced by the mixture of CD4-CD8 lipopeptide vaccine and the protective efficacy against

281 The lipopeptide vaccine and the rAdv5 vaccine express the im

282 tructure-activity relationship of the cyclic lipopeptide vaccine showed successful induction of J8-sp

283 and Pam(2)Cys to generate a self-adjuvanting lipopeptide vaccine.

284 Moreover, we demonstrate that a lipopeptide version of the same peptide is able to bind

285 This novel lipopeptide was membrane lytic and exhibited antibiofilm

286 lved in the synthesis of a virulence-related lipopeptide, was mis-annotated as a fatty acyl-CoA ligas

287 Daptomycin, a new cyclic lipopeptide, was recently approved for the treatment of

288 cifically blocked by L-protein-derived preS1-lipopeptides, we visualized specific HBV receptor/ligand

289 These lipopeptides were isolated from an inactivation mutant o

290 Structures for each of these lipopeptides were proposed based on amino acid analysis

291 Lipopeptides were self-assembled into nanoparticles or e

292 idus necator H16 produces a family of linear lipopeptides when grown under low iron conditions.

293 (CD) spectroscopy, we demonstrated that the lipopeptides, when incorporated into liposomes, are demi

294 Daptomycin is a lipopeptide with bactericidal activity that acts on the

295 Variations of this lipopeptide with different fatty acyl moieties (C16 fatt

296 Tridecaptin A1 (TriA1) is a nonribosomal lipopeptide with selective antimicrobial activity agains

297 Novel cyclic lipopeptides with different acyl tails were synthesized

298 crospheres coated with a synthetic Wolbachia lipopeptide (WoLP) of the major nematode Wolbachia TLR2/

299 Deletion of dptGHIJ reduced overall lipopeptide yield and led to production of a series of n

300 tool to guide the isolation of a new cyclic lipopeptide, yuvalamide A, from a marine cyanobacterium.